Research programme: Thrombosis therapeutics - Transtech PharmaAlternative Names: TTP 896
Latest Information Update: 23 Sep 2010
At a glance
- Originator TransTech Pharma
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 23 Sep 2010 Discontinued - Preclinical for Thrombosis in USA (unspecified route)
- 22 Nov 2006 Preclinical trials in Thrombosis in USA (unspecified route)